Climb Bio, Inc. (CLYM)
NASDAQ · Manufacturing · Pharmaceutical preparations
$11.66−$0.2300 (−1.93%) on the dayAs of the close; data may be delayed.
CLYM price, last 12 months
Key stats
- Previous close
- $11.89
- Open
- $11.89
- Day range
- $11.53 – $11.92
- 52-week range
- $1.54 – $18.33
- Volume
- 1.5M
- Avg volume (20 days)
- 1.9M
- Market cap
- $669.7M
Performance
1W−17.0%
1M−27.5%
3M−10.9%
6M+64.0%
YTD+191.5%
1Y+432.4%
vs S&P 500, 1Y+415.6 pts
Technicals and fundamentals
About Climb Bio, Inc.
Climb Bio Inc is a clinical-stage biotechnology company focused on developing therapeutics for patients with immune-mediated diseases. Its pipeline includes Budoprutug, an anti-CD19 monoclonal antibody being developed for B-cell mediated diseases such as primary membranous nephropathy, immune thrombocytopenia, and systemic lupus erythematosus, and CLYM116, an anti-APRIL monoclonal antibody being developed for the treatment of IgA nephropathy.
- Sector
- Manufacturing
- Industry
- Pharmaceutical preparations
- Listed on
- NASDAQ
- Market cap
- $669.7M